Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Crushing Prasugrel Tablets Does Not Help STEMI Patients

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

October 19, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

October 19, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Bivalirudin vs. Heparin in Acute Myocardial Infarction Patients

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

October 17, 2020

The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020

News | Stents Drug Eluting

Shorter DAPT With Xience Stent is Noninferior to Standard DAPT

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

October 16, 2020

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents

Medtronic Resolute Onyx Drug Eluting Stent First to Receive One-Month DAPT Indication

October 1, 2020 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual ...

October 01, 2020

hort-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients with COVID-19 (SARS-CoV-2) who are risk assessed prior to receiving the drug. That is the finding of research published today in EP Europace, a journal of the European Society of Cardiology (ESC). #COVID19 #SARSCoV2 #hydroxychloroquine

News | Coronavirus (COVID-19)

Short-term Hydroxychloroquine Use in COVID-19 Patients Does Not Cause Lethal Arrhythmias if Screened

September 25, 2020 — Short-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients ...

September 25, 2020

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

News | Coronavirus (COVID-19)

Statins May Reduce COVID-19 Severity

September 24, 2020 — Analyzing anonymized patient medical records, University of California (UC) San Diego Health resear ...

September 24, 2020

News | Coronavirus (COVID-19)

COVID-19 Therapy Drug Azithromycin May Increase Risk for Cardiac Events

September 17, 2020 — Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of C ...

September 17, 2020

The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.

News | Coronavirus (COVID-19)

NIH Trials Evaluate Various Blood Thinners to Treat COVID-19

September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials ...

September 11, 2020

Videos | Pharmaceuticals

VIDEO: Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David ...

September 10, 2020

Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial

News | Pharmaceuticals

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque ...

September 10, 2020

News | Coronavirus (COVID-19)

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin ...

September 08, 2020

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

News | Coronavirus (COVID-19)

Possible Blood Clotting Mechanism in COVID-19 Found

September 3, 2020 — Why so many COVID-19 (SARS-CoV-2) patients get blood clots (thrombosis) remains uncertain. But ...

September 03, 2020

Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.

News | Antiplatelet and Anticoagulation Therapies

Trial Shows Benefit of Using Genetic Testing to Tailor Antiplatelet Therapy

September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by ...

September 02, 2020

Dapagliflozin (Farxiga) heart failure drug performs very will to improve outcomes for patients with chronic kidney disease.

News | Pharmaceuticals

Dapagliflozin Meets All Endpoints to Treat Chronic Kidney Disease

July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of ...

July 28, 2020